Clinical Trials Logo

Hilar Cholangiocarcinoma clinical trials

View clinical trials related to Hilar Cholangiocarcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05239169 Active, not recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Start date: May 23, 2022
Phase: Phase 2
Study type: Interventional

This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized pick-the-winner design and an option to proceed into a randomized phase 2/3 trial in order to compare the winner with the current SOC (capecitabine).

NCT ID: NCT02042443 Active, not recruiting - Clinical trials for Advanced Adult Hepatocellular Carcinoma

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Start date: February 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving trametinib is more effective than combination chemotherapy in treating patients with biliary or gallbladder cancer.